1. COVID-19 and inflammatory bowel disease: A pathophysiological assessment
- Author
-
Chunxiu Yang and Shu-Yuan Xiao
- Subjects
COVID-19 ,SARS-CoV-2 ,Inflammatory bowel disease ,Therapy ,Cytokine release syndrome ,Immune response ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, has led to the ongoing global pandemic. Although most patients experience no or only mild symptoms, some patients can develop severe illness, such as progressive pneumonia, acute respiratory distress syndrome, secondary hemophagocytic lymphohistiocytosis and multiple organ failure caused by cytokine release syndrome. A majority of COVID-19 patients also develop gastrointestinal symptoms. These can present special challenges to the management of patients with inflammatory bowel disease (IBD) due to potential interactions between the immune response related to SARS-CoV-2 infection and dysregulated immunity associated with IBD. In this context, the pathogenesis of COVID-19 is reviewed in order to address these questions regarding immune interactions between COVID-19 and IBD.
- Published
- 2021
- Full Text
- View/download PDF